Literature DB >> 34409665

Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine-19 MRI.

Lawrence M Lechuga1, Matthew H Forsberg2, Kirsti L Walker2,3, Kai D Ludwig1, Christian M Capitini2,4,5, Sean B Fain1,4,5,6.   

Abstract

Natural killer (NK) cell therapies are being increasingly used as an adoptive cell therapy for cancer because they can recognize tumor cells in an antigen-independent manner. While promising, the understanding of NK cell persistence, particularly within a harsh tumor microenvironment, is limited. Fluorine-19 (19 F) MRI is a noninvasive imaging modality that has shown promise in longitudinally tracking cell populations in vivo; however, it has not been studied on murine NK cells. In this study, the impact of 19 F labeling on murine NK cell viability and function was assessed in vitro and then used to quantify NK cell persistence in vivo. While there was no noticeable impact on viability, labeling NK cells with 19 F did attenuate cytotoxicity against lymphoma cells in vitro. Fluorescent microscopy verified 19 F labeling in both the cytoplasm and nucleus of NK cells. Lymphoma-bearing mice were given intratumoral injections of 19 F-labeled NK cells in which signal was detectable across the 6 day observation period via 19 F MRI. Quantification from the composite images detected 78-94% of the initially injected NK cells across 6 days, with a significant decrease between Days 3 and 6. Postmortem flow cytometry demonstrated retention of 19 F intracellularly within adoptively transferred NK cells with less than 1% of 19 F-containing cells identified as tumor-associated macrophages that presumably ingested nonviable NK cells. This work demonstrates that 19 F MRI offers a specific imaging platform to track and quantify murine NK cells within tumors noninvasively.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MRI; adoptive cell therapy (ACT); flow cytometry; fluorescence microscopy; fluorine-19 (19F); in vivo imaging; natural killer cells (NKs)

Mesh:

Year:  2021        PMID: 34409665      PMCID: PMC8635739          DOI: 10.1002/nbm.4600

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  61 in total

1.  SENSE: sensitivity encoding for fast MRI.

Authors:  K P Pruessmann; M Weiger; M B Scheidegger; P Boesiger
Journal:  Magn Reson Med       Date:  1999-11       Impact factor: 4.668

2.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 3.  Noninvasive cell-tracking methods.

Authors:  Moritz F Kircher; Sanjiv S Gambhir; Jan Grimm
Journal:  Nat Rev Clin Oncol       Date:  2011-09-27       Impact factor: 66.675

4.  The Rician distribution of noisy MRI data.

Authors:  H Gudbjartsson; S Patz
Journal:  Magn Reson Med       Date:  1995-12       Impact factor: 4.668

5.  Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Authors:  Stefan O Ciurea; Jolie R Schafer; Roland Bassett; Cecele J Denman; Kai Cao; Dana Willis; Gabriela Rondon; Julianne Chen; Doris Soebbing; Indreshpal Kaur; Alison Gulbis; Sairah Ahmed; Katayoun Rezvani; Elizabeth J Shpall; Dean A Lee; Richard E Champlin
Journal:  Blood       Date:  2017-08-23       Impact factor: 22.113

6.  Chemical shift encoding (CSE) for sensitive fluorine-19 MRI of perfluorocarbons with complex spectra.

Authors:  Ruud B van Heeswijk; Roberto Colotti; Emeline Darçot; Jean Delacoste; Maxime Pellegrin; Davide Piccini; Diego Hernando
Journal:  Magn Reson Med       Date:  2017-09-01       Impact factor: 4.668

Review 7.  Fluorine-containing nanoemulsions for MRI cell tracking.

Authors:  Jelena M Janjic; Eric T Ahrens
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Sep-Oct

8.  Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers.

Authors:  Vivek Subbiah; Ravi Murthy; David S Hong; Robert M Prins; Chitra Hosing; Kyle Hendricks; Deepthi Kolli; Lori Noffsinger; Robert Brown; Mary McGuire; Siquing Fu; Sarina Piha-Paul; Aung Naing; Anthony P Conley; Robert S Benjamin; Indreshpal Kaur; Marnix L Bosch
Journal:  Clin Cancer Res       Date:  2018-07-17       Impact factor: 12.531

9.  90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

Authors:  Reinier Hernandez; Kirsti L Walker; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Ravi Patel; Christopher D Zahm; Anatoly N Pinchuk; Christopher F Massey; Ariana N Bitton; Ryan J Brown; Paul M Sondel; Zachary S Morris; Jonathan W Engle; Christian M Capitini; Jamey P Weichert
Journal:  Commun Biol       Date:  2019-02-26

10.  Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI.

Authors:  Eric T Ahrens; Brooke M Helfer; Charles F O'Hanlon; Claudiu Schirda
Journal:  Magn Reson Med       Date:  2014-09-19       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.